Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities

Curr Treat Options Oncol. 2020 Mar 14;21(4):25. doi: 10.1007/s11864-020-0711-9.

Abstract

Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms characterized by varied biological hallmarks and behavior, ranging from indolent to aggressive. For many decades, somatostatin analogues and few targeted therapies were available for NETs and these therapies had minimal response rates. However, there have been a number of recent treatment advances. Peptide receptor radionuclide therapy (PRRT) is a novel approach to treatment of NETs and has changed the landscape of treatment for NETs. It is a form of targeted therapy in which a radiolabeled somatostatin analogue delivers radiation specifically to tumor cells expressing the somatostatin receptor.

Keywords: Myelodysplastic syndrome (MDS; Peptide receptor radionuclide therapy (PRRT); Salvage therapy; Somatostatin analogues (SSAs); Somatostatin receptors (SSTRs); Toxicity.

Publication types

  • Review

MeSH terms

  • Biomedical Research
  • Brachytherapy / adverse effects*
  • Brachytherapy / methods
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neuroendocrine Tumors / etiology
  • Neuroendocrine Tumors / pathology*
  • Neuroendocrine Tumors / therapy*
  • Patient Selection*
  • Practice Guidelines as Topic
  • Radiation Dosage
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / adverse effects*
  • Receptors, Peptide / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Receptors, Peptide